跳至主要内容
临床试验/NCT03063749
NCT03063749已完成不适用

A Post-approval Study of the Medtronic Resolute Onyx™ Zotarolimus-Eluting Coronary Stent System

Medtronic Vascular28 个研究点 分布在 4 个国家目标入组 416 人开始时间: 2017年3月30日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
416
试验地点
28
主要终点
Target Lesion Failure

研究概览

简要总结

To observe the continued performance of the Medtronic Resolute Onyx™ Zotarolimus-Eluting Coronary Stent System in a real-world more-comer population.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • 未提供

排除标准

  • 未提供

结局指标

主要结局

Target Lesion Failure

时间窗: 12 months

Target Lesion Failure (TLF), defined as cardiac death, target vessel myocardial infarction (Q wave and non-Q wave), or clinically driven target lesion revascularization (TLR) by percutaneous or surgical methods

次要结局

  • Acute Success (Device, Lesion, Procedure)(30 days and 6, 12, 24, and 36 months post-procedure)
  • Target Vessel Myocardial Infarction (TVMI)(30 days and 6, 12, 24, and 36 months post-procedure)
  • Target Lesion Revascularization (TLR)(30 days and 6, 12, 24, and 36 months post-procedure)
  • Cardiac Death and TVMI(30 days and 6, 12, 24, and 36 months post-procedure)
  • Major Adverse Cardiac Event (MACE)(30 days and 6, 12, 24, and 36 months post-procedure)
  • Target Vessel Revascularization (TVR)(30 days and 6, 12, 24, and 36 months post-procedure)
  • Target Lesion Failure (TLF)(30 days and 6, 12, 24, and 36 months post-procedure)
  • Cardiac Death(30 days and 6, 12, 24, and 36 months post-procedure)
  • Target Vessel Failure (TVF)(30 days and 6, 12, 24, and 36 months post-procedure)
  • Stent Thrombosis (ST)(30 days and 6, 12, 24, and 36 months post-procedure)

研究者

发起方
Medtronic Vascular
申办方类型
Industry
责任方
Sponsor

研究点 (28)

Loading locations...

相似试验